ANIMAL HEALTH GLOBAL TRENDS IN 2021 AND 2022 PERSPECTIVES

HOW WAS 2021 IN ANIMAL HEALTH? WHAT WERE THE BIG TRENDS? WHAT TO EXPECT FOR THE START OF 2022?

2021 Closed with clear trends in both, the global and the LATIN AMERICAN Markets. Global ANIMAL HEALTH market grew driven by PET (adoption and proximity), disease outbreaks (Pork and Livestock) and technology. Technological advances are driven by e-commerce/payment methods, e-learning platforms, mobile applications, and diagnostic/monitoring and telehealth initiatives. The horse market is still depressed due to the new variants of Covid 19 impacting Horse Sports and exhibitions.

Generic Market is gaining importance in ASIA-PACIFIC and LATIN AMERICA but also in the US and EU (60% of new launches) based on price erosion and big promotions.

But still, global big multinationals are in the top of the sales based in brand awareness and marketing strategies and combined portfolios with some innovative formulations and good loyalty and compliance strategies.

Global animal trade growth, led by increased Swine and Poultry demand in Asia and Africa, benefits growth potential of LATAM livestock.

LATAM ANIMAL HEALTH market is expected to continue growing driving leading by Companion Animal, technology penetration, vaccine market development and at lesser extent other health segments such as antibiotics. The three LATIN AMERICAN giants (Ourofino, Lapisa and Biogenesis Bago) are leading in the region.

GLOBAL COMPANY ACTIVITIES DURING 2021

?? Bimeda received FDA approval for SelaSpot (generic selamectin) in dogs and cats January 2021, ?Macrosyn (generic tulathromycin) February 2021 and FDA approval for KetoMed generic ketoprofen in April. In Latinamerica growth continues in Colombia, Mexico and Brazil (Mogivet)

?? Biogenesis Bagó, the biotechnology company was distinguished with the Mercury Prize 2021 in the Veterinary category granted by the Argentine Marketing Association (AAM). They also received a comitee of Saudi Arabia and the ambassador Hussein M. Alassiri in their facilities in Garin and were discussing on a project to start manufacturing F&M Vaccines in that country. The expansion in Brazil (the main LATAM Market) is growing in over 3k municipalities. They are now investing 14 M USD in the antigen bank.

?? Boehringer Ingelheim signed agreement with PetMedix to develop companion animal antibody therapeutics that is a trend to differentiate the proposal. They also signed with Saiba Animal Health to develop monoclonal antibodies for companion animals using Saiba’s VPL vaccine platform and also with Invetx. In July this year it was launched Bovikalc (dry mineral supplement). Additionally they created Pawru as a separate company within the Animal Health Business to encompass & expand its digital animal health platform. In Latin America the trend was to grow in Avian Vaccines and started engage the One Health concept.

?? Chr. Hansen creates the Pets Health & Nutrition branch of the company in the US Market. They have weak presence in Latin America.

?? Chanelle Pharmaceuticals receives FDA approval for Animec Plus (generic ivermectin/clorsulon) March 2021 and Parasedge Multi (generic imidacloprid & moxidectin). The presence of the company in the Latin American Market is still poor.

?? Dechra received FDA approval for generic carprofen tablets and marketing & distribution rights to ProVet APC and BMC from Hassinger Biomedical in the US Market. They also launched Solupam (inj. solution of Diazepam) in Spain and Equisolon (the only registered powder formulated oral corticosteroid for horses) and Equishield EHV (the new vaccine against Equine Herpesvirus type-1 (EHV-1). They also received FDA approval for generic Amoxicillin and Clavulanate Potassium Oral Suspension in September

?? Elanco received FDA approval for Increxxa (generic tulathromycin) (February 2021), Elura (capromorelin) weight loss management treatment for cats, Credelio (lotilaner) Cat parasite treatment, ZoaShield (zoalene) for poultry coccidia, and agreed with EVAH Corp to develop feed additives and vaccines. In Latin America they are in the process of portfolio rationalization and focusing in the restructuring process.

?? JA Saúde Animal announced an investment agreement with an Equity Investment Fund (FIP) managed by the Axxon Group. With the transaction, FIP becomes a relevant minority partner of the company with the objective of continuing its history of innovation and accelerated growth.

?? In May LAPISA Animal Health (Mexico) and the CEO Francisco Romo, and the head of Lapisa's expansion project, Juan Pablo Ostos, announced the arrival of the Mexican giant in Colombia. Pedro José Sánchez, with a track record of more than 25 years working with and for the agricultural sector in the country, is in charge of managing the execution and implementation of the project in the field, served from Bogotá.

?? Norbrook launched Cefenil RTU (generic) for swine in the US Market and in Latin America they continue focusing in the tiering process cross market/customers.

?? Ourofino Saude Animal received the 23rd Annual Report Abrasca Prize, of the Brazilian Association of Open Companies, on the sustainability of open capital companies with the completion of 3 bilh?es de reais. In addition they entered in the Stem Cell therapy Market.

?? The Vansil Group presents to the market its new Chief Executive Officer (CEO), Ricardo Jossi de Oliveira, who has been working in the organization for 17 years, achieving great success in all of his functions, which directly contributed to the growth of Vansil Saúde Animal and all its member companies of the group. Graduated in veterinary medicine from the University of Marília, Ricardo Oliveira also holds a degree in veterinary medicine.

?? Vetoquinol launched Clevor (ropinirole) April 2021, Phovia light application to accelerate skin regeneration, Imoxi (generic imidacloprid & moxidectin) for Dogs.

?? Virbac and Phibro signed an agreement for Phibro to market Virbac’s Tussilin (generic tulathromycin) in Canada, and launched Cyclavance (cyclosporine oral solution). In addition Virbac and SymbioCellTech LLC sign agreement to develop SCT’s cellular therapy for diabetes and with Jectas Innovators sign agreement to develop animal health vaccines. In Latin America they continue to develop acquisitions in Uruguay (Santa Elena), Chile (Centrovet) with good growth in the CA portfolio.

?? Zoetis received EU marketing approval for Solensia (frunevetmab) monthly monoclonal antibody for osteoarthritis treatment in cats, launched Librela (bedinvetmab) monthly monoclonal antibody for osteoarthritis in dogs in Europe, Pro-Stride APS, Restigen PRP and CenTrate BMA for the equine market and received FDA approval for Draxxin KP (tulathromycin & ketoprofen) for cattle. They invested U$ 53M in the facilities in Gerona (Spain). In Latin America Chile’s largest zoo was the first Zoo in Latin America to inoculate animals against Covid-19 using an experimental vaccine developed by Zoetis.

BERNARDO OTERO (Ceo & Founder of Nexus Animal Health)

www.animalhealthnexus.com